A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis.

@article{Dell1998ARD,
  title={A randomized, double-masked, placebo-controlled parallel study of 0.2\% loteprednol etabonate in patients with seasonal allergic conjunctivitis.},
  author={Steven J. Dell and G M Lowry and Joanne Northcutt and John F. Howes and Gary D. Novack and K Hart},
  journal={The Journal of allergy and clinical immunology},
  year={1998},
  volume={102 2},
  pages={
          251-5
        }
}
View on PubMed
doi.org
74 Citations
Highly Influential Citations
4
Background Citations
25
Methods Citations
1
Results Citations
2

74 Citations

A multicenter, randomized, parallel-group, clinical trial comparing the safety and efficacy of loteprednol etabonate 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of Chinese patients with blepharokeratoconjunctivitis

Treatment with LE/T was at least as effective as DM/T in Chinese patients with BKC and had a better safety profile with respect to change in IOP.

Loteprednol etabonate suspension 0.2% administered QID compared with olopatadine solution 0.1% administered BID in the treatment of seasonal allergic conjunctivitis: a multicenter, randomized, investigator-masked, parallel group study in Chinese patients.

Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis

Similar efficacy of three medications in relieving symptoms and inefficacy in regressing palpebral and limbal papillae in cases of allergic conjunctivitis is concluded.

Long-term Safety of Loteprednol Etabonate 0.2% in the Treatment of Seasonal and Perennial Allergic Conjunctivitis

Loteprednol etabonate 0.2% is a safe topical steroid when used on a long-term basis for the treatment of seasonal and perennial allergic conjunctivitis.

Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Loteprednol Etabonate US Uveitis Study Group.

Efficacy and safety of loteprednol etabonate 0.5% gel in the treatment of ocular inflammation and pain after cataract surgery

Comparative Research on the Effectiveness and Safety of Long- Acting Antihistamines in Allergic Conjunctivitis in Indian Patients: An RCT Trial

Alcaftadine was found to be better than olopatadine in reducing the Allergic Conjunctivitis symptoms using TOSS score at 14th day visit and bepotastine showed a better reduction of symptoms.

In allergic conjunctivitis, a comparison of the safety and effectiveness of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2%, and Bepotastine besilate 1.5%

All three topical ophthalmic medications used in the study are safe and effective in the treatment of allergic conjunctivitis, however, Bepotastine and Alcaftadine appear to outweigh Olopatadine in resolving the symptoms of allergies.

A Randomized Prospective Open Label Comparative Study of Olopatadine with Sodium Cromoglycate in Allergic Conjunctivitis

Both 0.2%olopatadine and 2% sodium cromoglycate are effective in treating allergic conjunctivitis and both drugs are safe and well tolerated.

In Allergic Conjunctivitis, Comparative Assessment of the Safety and Effectiveness of Alcaftadine 0.25 Percent, Olopatadine Hydrochloride 0.2 Percent, and Bepotastine Besilate 1.5 Percent

Conjunctival hyperaemia had reduced in all the treatment groups but there was a significant reduction in Alcaftadine and Bepotastine treatment groups at 14th day compared to olopatadine group, but this was not statistically significant.
...

References

SHOWING 1-10 OF 11 REFERENCES

A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis.

  • P. AsbellJ. Howes
  • Medicine
    The CLAO journal : official publication of the Contact Lens Association of Ophthalmologists, Inc
  • 1997

A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Loteprednol Allergic Conjunctivitis Study Group.

Intraocular pressure response to loteprednol etabonate in known steroid responders.

LE has less effect on IOP when compared to the IOP response induced by PA, and LE may become a clinically useful ocular steroid with a favorable IOP-safety profile.

Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes.

Levels of LE and its metabolites were highest in the cornea, and so was the ratio of metabolites to unchanged drug, suggesting that the primary site of deactivation of the drug is the corneal tissue.

Conjunctivitis of allergic origin: clinical presentation and differential diagnosis.

Ocular pressure response to fluorometholone acetate and dexamethasone sodium phosphate.

The intraocular pressure elevating potentials of fluorometholone acetate ophthalmic suspension and dexamethasone sodium phosphate ophthalic solution were compared in human subjects who were previously documented to respond to dexamETHasone Sodium phosphate, and the difference, in favor of fluoride acetate, is statistically significant.

Adverse nondrug reactions: An update

Statistical analysis of multi-eye data in ophthalmic research.

  • W. RayD. O'Day
  • Medicine
    Investigative ophthalmology & visual science
  • 1985
Increased emphasis on educational programs for investigators, stimulation of nontechnical articles reviewing statistical methods, and a sharper focus upon statistical analysis in the peer review process are recommended to reduce the occurrence of this serious error in statistical analyses.

Adverse nondrug reactions.

Abstract Healthy university students and hospital staff taking no medications were surveyed by questionnaire to obtain data on the occurrence of many symptoms often listed as side effects of drugs....

Novel approaches to the design of safer drugs: soft drugs and site-specific chemical delivery systems